-DOCSTART-

Transformation NN O O
of NN O O
chronic NN O O
lymphocytic NN O O
leukaemia NN O O
( NN O O
CLL NN O O
) NN O O
to NN O O
diffuse NN O O
large NN O O
B-cell NN O O
lymphoma NN O O
( NN O O
DLCBL NN O O
) NN O O
type NN O O
Richter NN O O
's NN O O
syndrome NN O O
( NN O O
RS NN O O
) NN O O
carries NN O O
a NN O O
dismal NN O O
prognosis NN O O
. NN O O

Standard-of-care NN O O
chemoimmunotherapy NN O O
for NN O O
de NN O O
novo NN O O
RS NN O O
is NN O O
inadequate NN O O
with NN O O
median NN O O
survival NN O O
of NN O O
less NN O O
than NN O O
one NN O O
year NN O O
. NN O O

Patients NN O O
are NN O O
frequently NN O O
elderly NN O O
or NN O O
have NN O O
co-morbidities NN O O
limiting NN O O
dose-intense NN O O
chemotherapy NN O O
. NN O O

Treatment NN O O
of NN O O
relapsed/refractory NN O O
( NN O O
R/R NN O O
) NN O O
RS NN O O
and NN O O
RS NN O O
emerging NN O O
after NN O O
CLL-directed NN O O
therapy NN O O
represent NN O O
urgent NN O O
unmet NN O O
clinical NN O O
needs NN O O
. NN O O

Agents NN O O
targeting NN O O
Bruton NN O O
's NN O O
tyrosine NN O O
kinase NN O O
( NN O O
BTK NN O O
) NN O O
deliver NN O O
improved NN O O
outcomes NN O O
for NN O O
patients NN O O
with NN O O
high-risk NN O O
CLL NN O O
and NN O O
expand NN O O
effective NN O O
treatments NN O O
to NN O O
frailer NN O O
patients NN O O
. NN O O

Acalabrutinib NN O O
is NN O O
an NN O O
oral NN O O
, NN O O
second-generation NN O O
BTK NN O O
inhibitor NN O O
with NN O O
a NN O O
favourable NN O O
toxicity NN O O
profile NN O O
and NN O O
demonstrated NN O O
activity NN O O
in NN O O
CLL NN O O
and NN O O
B-cell NN O O
lymphomas NN O O
. NN O O

Combination NN O O
of NN O O
acalabrutinib NN O O
with NN O O
standard-of-care NN O O
CHOP-R NN O O
chemoimmunotherapy NN O O
offers NN O O
a NN O O
sound NN O O
rationale NN O O
to NN O O
test NN O O
in NN O O
a NN O O
prospective NN O O
trial NN O O
for NN O O
de NN O O
novo NN O O
RS NN O O
. NN O O

The NN O O
prospective NN O O
multicentre NN O O
STELLAR NN O O
study NN O O
is NN O O
designed NN O O
in NN O O
two NN O O
elements NN O O
, NN O O
consisting NN O O
of NN O O
a NN O O
randomised NN O O
study NN O O
to NN O O
evaluate NN O O
the NN O O
safety NN O O
and NN O O
activity NN O O
of NN O O
CHOP-R NN O O
chemoimmunotherapy NN O O
in NN O O
combination NN O O
with NN O O
acalabrutinib NN O O
in NN O O
newly NN O O
diagnosed NN O O
RS NN O O
and NN O O
single-arm NN O O
studies NN O O
of NN O O
novel NN O O
agents NN O O
for NN O O
other NN O O
RS NN O O
patient NN O O
cohorts NN O O
. NN O O

Eligible NN O O
patients NN O O
with NN O O
newly NN O O
diagnosed NN O O
DLBCL-type NN O O
RS NN O O
are NN O O
randomised NN O O
between NN O O
six NN O O
cycles NN O O
of NN O O
CHOP-R NN O O
therapy NN O O
and NN O O
six NN O O
cycles NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
, NN O O
followed NN O O
by NN O O
acalabrutinib NN O O
maintenance NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
of NN O O
the NN O O
randomised NN O O
component NN O O
is NN O O
progression NN O O
free NN O O
survival NN O O
( NN O O
PFS NN O O
) NN O O
. NN O O

Cohort NN O O
1 NN O O
enrols NN O O
RS NN O O
patients NN O O
with NN O O
progressive NN O O
disease NN O O
following NN O O
chemoimmunotherapy NN O O
for NN O O
acalabrutinib NN O O
monotherapy NN O O
. NN O O

Patients NN O O
with NN O O
RS NN O O
diagnosed NN O O
while NN O O
on NN O O
ibrutinib NN O O
may NN O O
enrol NN O O
in NN O O
Cohort NN O O
2 NN O O
, NN O O
a NN O O
single-arm NN O O
study NN O O
of NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
. NN O O

The NN O O
primary NN O O
endpoint NN O O
for NN O O
the NN O O
single-arm NN O O
studies NN O O
is NN O O
overall NN O O
response NN O O
rate NN O O
( NN O O
ORR NN O O
) NN O O
. NN O O

Secondary NN O O
endpoints NN O O
for NN O O
all NN O O
cohorts NN O O
are NN O O
overall NN O O
survival NN O O
( NN O O
OS NN O O
) NN O O
, NN O O
quality NN O O
of NN O O
life NN O O
and NN O O
proportion NN O O
of NN O O
patients NN O O
proceeding NN O O
to NN O O
stem NN O O
cell NN O O
transplantation NN O O
. NN O O

The NN O O
study NN O O
will NN O O
be NN O O
accompanied NN O O
by NN O O
exploratory NN O O
analysis NN O O
of NN O O
the NN O O
mutational NN O O
landscape NN O O
of NN O O
RS NN O O
and NN O O
the NN O O
relationship NN O O
between NN O O
dynamic NN O O
changes NN O O
in NN O O
sequential NN O O
circulating NN O O
tumour NN O O
DNA NN O O
samples NN O O
and NN O O
clinical NN O O
outcomes NN O O
. NN O O

The NN O O
STELLAR NN O O
randomised NN O O
trial NN O O
evaluates NN O O
the NN O O
role NN O O
of NN O O
CHOP-R NN O O
plus NN O O
acalabrutinib NN O O
in NN O O
newly NN O O
diagnosed NN O O
RS NN O O
patients NN O O
. NN O O

The NN O O
single-arm NN O O
platform NN O O
studies NN O O
enable NN O O
the NN O O
incorporation NN O O
of NN O O
promising NN O O
novel NN O O
therapies NN O O
into NN O O
the NN O O
protocol NN O O
. NN O O

The NN O O
STELLAR NN O O
study NN O O
has NN O O
potential NN O O
to NN O O
identify NN O O
novel NN O O
biomarkers NN O O
of NN O O
treatment NN O O
response NN O O
in NN O O
this NN O O
high-risk NN O O
malignancy NN O O
